This honor not only serves as authoritative recognition of EndoFresh®'s technical strength but also provides strong policy support for the market promotion and application of the company's products.
Authoritative Certification, Demonstrating Innovative Strength
The "Shenzhen Innovative Products Promotion and Application Catalog" is jointly released by the Shenzhen Industrial and Information Technology Bureau and the Shenzhen Finance Bureau. It aims to select innovative products with independent intellectual property rights, advanced technology, and broad market prospects, promoting supply-demand matching through government platforms and helping enterprises expand their market.
The EndoFresh® Single-Use Gastrointestinal Endoscope 300 Series stood out among numerous evaluated products with its core advantages such as high-definition imaging, single-use design, and user-friendly operation, establishing itself as an innovative benchmark in the medical field.
Policy Empowerment, Accelerating Market Expansion
Following its inclusion in the Catalog, the EndoFresh® Single-Use Gastrointestinal Endoscope 300 Series encounters significant opportunities for market promotion.
-
Government Platform Display: The Shenzhen Industrial and Information Technology Bureau has established an "Innovative Products" section on the "Shenzhen iEnterprise" platform (Domestic and Foreign Trade Integration category), entrusting Shenzhen Smart Enterprise Service Co., Ltd. to uniformly list and display the products included in the catalog.
-
Government Procurement Support: The Shenzhen Finance Bureau, jointly with the Shenzhen Public Resource Trading Center, has set up an "Industry Pavilion" within the government procurement e-mall, providing a dedicated display window for innovative products.
These initiatives not only accelerate the product's marketization process but also provide strong policy support for the company to expand its reach to government and high-end medical sector clients.
Innovation-Driven, Serving Healthy China
As China's healthcare industry enters a new stage of high-quality development, innovative medical devices centered on original technology and guided by clinical value are facing an unprecedented period of strategic opportunity. Amidst the wave of explosive growth in the single-use endoscopy market (reaching RMB 1.86 billion in 2024, according to Bricks Consulting (2025 Report)), the EndoFresh® Single-Use Gastrointestinal Endoscope 300 Series, with its groundbreaking "one person, one scope, single-use" design, fundamentally addresses the pain point of cross-contamination associated with traditional endoscopes. Its precise diagnostic and therapeutic performance also aligns closely with clinical needs, making it a benchmark product among domestically innovated medical devices. This innovative product creates significant social value across multiple dimensions:
-
Solves Infection Challenges, Reduces Healthcare Costs: The single-use design of EndoFresh® completely eliminates the hidden risk of infection, achieving "zero risk" in diagnosis and treatment. Full lifecycle cost analysis indicates it can reduce the overall burden on the healthcare system, shifting the endoscope model from a fixed asset to a consumable, significantly improving diagnostic and treatment efficiency.
-
Promotes Resource Allocation to Grassroots Levels, Supports Tiered Healthcare:
-
Aligns with Policy Requirements, Leads Industry Standards: New regulations in 2025 strengthen requirements for infection prevention, control, quality, and safety. EndoFresh®'s "zero infection risk" characteristic provides technical support for medical institutions to meet standards, driving the industry's upgrade from "result monitoring" to "source prevention."
-
Practices Healthy China, Demonstrates Technological Original Intention:
The successful inclusion of the EndoFresh® Single-Use Gastrointestinal Endoscope 300 Series in the Catalog marks authoritative recognition of the product's technological advancement and clinical value, injecting strong policy momentum into the company's development. With the deepening of the "Healthy China" strategy and the full rollout of colorectal cancer screening in 2025, EndoFresh®, empowered by both government procurement and platform promotion, is accelerating its strategic layout across the national market. The product, centered around 2-megapixel high-definition imaging, single-use sterility, and portable operation, combined with a highly integrated portable host and AI-assisted diagnostic system, ensures precise treatment and cross-contamination prevention and control, while significantly enhancing operational portability and diagnostic consistency in primary care settings.
We expect EndoFresh® to seize this opportunity and, driven by both policy and clinical needs, continuously broaden treatment scenarios and accelerate large-scale coverage in primary medical institutions. Through standardized operating procedures and intelligent assisted diagnosis, it will systematically lower the barrier to use at the grassroots level and improve the efficiency and accuracy of diagnosing digestive tract diseases. In the future, EndoFresh® is committed to becoming a vital supporting force in enhancing China's precision diagnosis and treatment capabilities for gastrointestinal tumors and within the independent innovation system for high-end medical devices.